Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-53

It is the sales person in me, asking, if others can, why can't I? Next step would be to analyse the competition and learn from them, then going out in the " field" and applying their better strategy. That's what I would do and would have done. Unfortunately I am not allowed to sell this week's great anns to those who value that and previous accomplished result(s).

Dare to be arrogant - I would achieve a better valuation then just $10-15m for CHM or a negative / below cash valuation ( RAD ) when ALA can easily sustain above $150m. If ALA and many others were valued ZERO too, I would keep my mouth shut or my typing hands off the keyboard. But they aren't.

I am more than happy to get a huge back lash from you all if he raises at favourable terms but I am afraid it will be me writing " I told you so! "

GLTA